00228289203
Duloxetine
Product Images NDC 50436-2892
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50436-2892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (Duloxetine 1)
6 (Duloxetine 10)
7 (Duloxetine 11)
This appears to be a chart showing the percentage of patients who have had pain improvement from baseline (BOCF) with different values ranging from 0 to 100. There are also numbers on the side, possibly indicating measurements or time periods. The text may have been intended to be part of a medical report or study.*
8 (Duloxetine 12)
1 (Duloxetine 13)
The text provides us with a chart that shows the percentage of patients improved with the help of a treatment or therapy. The chart presents data for different levels of pain improvement, ranging from 0 to 100 percent. It seems to be a useful tool for evaluating the effectiveness of a particular treatment or therapy in improving patient outcomes.*
1 (Duloxetine 2)
1 (Duloxetine 3)
1 (Duloxetine 4)
1 (Duloxetine 5)
This is a graph displaying the proportion of patients with relapse for a placebo group and those receiving treatment with pyjoxatine Extended-Release Capsules over time from randomization and relapse in days. The x-axis shows the time from randomization and relapse (in days) while the y-axis represents the proportion of patients with relapse. The placebo group is represented by a blue line while the treatment group is not shown.*
2 (Duloxetine 6)
The text represents a graph displaying the proportion of patients experiencing a relapse over time after being randomized to receive either a placebo or Duloxetine Delayed-Release. The x-axis represents time in days, while the y-axis represents the proportion of patients. The graph shows that fewer patients in the Duloxetine Delayed-Release group experienced a relapse compared to those in the placebo group over the course of the study.*
3 (Duloxetine 7)
4 (Duloxetine 8)
1 (Duloxetine 9)
Label Image (Lbl504362892)
This is a medication description for Duloxetine Hydrochloride in delayed-release capsules with strength 60mg/30 caps. The package includes manufacturing information, lot numbers, and expiration dates. It is prescribed for depression and anxiety disorders. The medication should be kept out of the reach of children and should be stored at room temperature. However, some text is not available due to the quality.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
